Patients with rare scleroderma have deadlier organ damage, despite getting standard treatment

Researchers say it’s a sign that more targeted therapies are needed for the vulnerable patient population.

5:00 AM

Author | Noah Fromson

Patient holding hand with doctor wearing medical glove
Credit: Jacob Dwyer, Michigan Medicine

A Michigan Medicine-led study found that patients in the United States with a rare form of scleroderma have a greater chance of dying from related kidney, heart and lung problems, despite taking medications used to treat most patients with the disease.

The research team assessed more than 300 patients diagnosed with, or at risk for, early diffuse systemic sclerosis, a form of the autoimmune condition marked by more tightening of the skin that can also affect internal organs. The participants were treated at 12 different scleroderma centers in the U.S. between 2011 and 2020 – one of the largest sub-populations of individuals with the orphan disease ever studied in the U.S.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.

The results, published in Arthritis Research & Therapy, reveal that the immunosuppressive therapies given to most patients with early diffuse systemic sclerosis have minimal effects at changing the progression of the disease in the long term.

"Despite using the standard of care therapies, patients continue to have worse thickening of their skin and internal organ involvement, including lung scarring that has an impact on their disability, function and survival," said Dinesh Khanna, M.B.B.S., M.Sc., corresponding author of the paper, professor of rheumatology at Michigan Medicine and director of U-M's Scleroderma Program. "This leads to significant damage to the internal organs and an increased likelihood of death due to heart, gut and lung involvement."

SEE ALSO: Potential biomarker found for lung disease in scleroderma patients

Nearly two-thirds of the subjects were treated with Mycophenolate Mofetil, commonly referred to as MMF. The immunosuppressive therapy is not FDA approved but is used by most physicians for the management of the condition.

This is a clear opportunity to find new therapies that would improve patients' quality of life, decrease the internal organ involvement and, therefore, improve survival rates.
Dinesh Khanna, MBBS, MSc

Of all participants, 23% lost forced vital capacity by 10% or more. Just over 6% of the subjects died from causes including cardiac failure and progressive lung disease.

"This multi-center U.S. cohort demonstrates the progression of skin and lung involvement despite immunosuppressive therapy, and high mortality due to cardiac involvement," said Sara Jaafar, M.D., lead author of the paper and a physician working at the U-M Scleroderma Program. "Our results confirm the overall high progressive trajectory for the worsening of forced vital capacity due to lung scarring, the third most common cause of systemic sclerosis-related deaths."

MORE FROM THE LAB: Subscribe to our weekly newsletter

Two drugs are currently FDA approved to treat lung scarring, or pulmonary fibrosis, that occurs as a result of scleroderma: nintedanib and tocilizumab. The latter, an anti-inflammatory drug used to treat rheumatoid arthritis, recently showed promising results in preserving lung function in systemic sclerosis patients when detected early.

SEE ALSO: Repurposing Tocilizumab in Scleroderma Patients May Prevent Early Lung Disease

The trial suggests a window of opportunity for tocilizumab to prevent irreversible health consequences. But Khanna believes this information should also inspire continued, targeted drug development for early diffuse scleroderma.

"This form of scleroderma has the highest fatality rate of any rheumatic disease," he said. "This is a clear opportunity to find new therapies that would improve patients' quality of life, decrease the internal organ involvement and, therefore, improve survival rates."

Paper cited: "Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort," Arthritis Research & Therapy. DOI: 10.1186/s13075-021-02548-1

Disclosures: Read the full list of Khanna's grants and personal fees from several organizations related to this research.

More Articles About: Lab Report Rheumatology Lung Disease Lung Function Pulmonary Fibrosis Medication Guidelines Lungs and Breathing
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine



Get a weekly digest of medical research and innovation, straight to your inbox.

Featured News & Stories Courtney Weirauch and family
Health Lab
A rare diagnosis and a young mother who’s spreading the word
Courtney Weirauch didn’t know what lymphangioleiomyomatosis was – but she quickly learned about the rare lung condition and how it would impact her life.
microscope cells glioma
Health Lab
Researchers circumvent radiation resistance in subtype of brain tumors
University of Michigan Rogel Cancer Center researchers find ZMYND8 gene plays a critical role in conferring radiation resistance on brain tumors with IDH1 mutation.
tavr stroke blue cardiovascular red inside blue background
Health Lab
Hospitals without highest stroke care designation may miss them after heart procedure
Using stroke as a measure of quality after TAVR could put stroke centers at a disadvantage, the study suggests
gas stove pot cooking
Health Lab
Is your gas stove really hurting you and your family?
A pulmonologist discusses the risks and offers tips for protecting your health in your home
cancer cells microscope blue green
Health Lab
Certain gene signaling rewires tumors after immunotherapy
For some patients, immunotherapy furthers tumor progression instead of halting it. What distinguishes those who benefit from those who don’t?
Brain wiring diagram prosthetic hand
Health Lab
Simple neural networks outperform the state-of-the-art for controlling robotic prosthetics
Simple neural networks outperform the state-of-the-art for controlling robotic prosthetics